Kazakhstan Pharmaceuticals and Healthcare Report Q3 2010 of Business Monitor International now available at ReportsandReports

Top Quote BMI retains its robust five-year growth forecast for the Kazakhstan pharmaceutical market, with the US dollar value of the market rebounding on the back of a resurgent local currency in 2010. End Quote
  • (1888PressRelease) July 22, 2010 - Dallas, TX: ReportsandReports announce it will carry Kazakhstan Pharmaceuticals and Healthcare Report Q3 2010 Market Research Report in its Store.

    Browse complete Report on: http://www.reportsandreports.com/market-reports/kazakhstan-pharmaceuticals-and-healthcare-report-q3-2010/

    Our forecast sees a strong economy - driven by increasing oil and gas output and anticipated strong global prices for these exports - and appreciating currency over five-year and ten-year forecast periods. BMI calculates a compound annual growth rate (CAGR) in US dollar terms of 17.47% for 2009-2014. Full-year data for 2009 showed an 18-22% boost in market value in local terms, with a slight contraction in US dollar value.

    For Kazakhstan's bureaucrats and pharmaceutical producers, the goal is to deliver tangible increases in domestic production to meet President Nursultan Nazarbayev's target of ensuring that 50% of medicines, in volume terms, are domestically sourced by 2014. Local production, according to the Farmmedindustriya industry association, increased by 23.4% to KZT12.4bn (US$83.7mn) in 2009. A decisive factor in supporting local output will be state purchasing. State-owned distributor SK Farmatsiya reported an increase in its share of domestically-sourced purchasing in 2009 from 8% to 23%, in volume terms. Officials say the country is on course to meet the 2014 deadline, while the country has adopted an industrial plan for the industry and a number of new production facilities are in the pipeline.

    To date there has been little tangible impact from the Customs Union of Kazakhstan, Russia and Belarus launched at the beginning of 2010. BMI's view is that the union is less important in terms of internal pharmaceutical trade - at least during the forecast period - but a significant player amid plans to harmonise market authorisation and other regulatory standards. Harmonisation, if achieved, could make these three key CIS markets easier to navigate for all players - an important development. However, some major regulatory gaps remain in Kazakhstan, such as the absence of a finalised set of local Good Manufacturing Practice (GMP) standards - despite a 2014 GMP compliance deadline - and a need to develop the country's formulary system and link it to the Essential Drugs List.

    The country's pipeline of domestic production projects represents, potentially, the most far-reaching development for the local sector since privatisation in the 1990s and BMI estimates the value of current projects at around US$200mn, a multiple of current industry value. Crucially, many of these projects require funding from the Kazakhstan Development Bank (KDB) and National Innovation Fund, as the once-strong private banking sector has yet to recover from the global financial crisis. The furthest advanced project among locals is one by domestic champion Chimpharm to build a new tablet factory in a new industrial park in Astana. The company also has plans to expand production facilities in Shymkent. Other players, including GlobalPharm, Nobel AFF, and Romat are reportedly planning new lines or new plants. If funding can be found in the state and private sector for these projects and the country can remain politically and economically stable, Kazakhstan will have an industry capable of meeting a significant share of local needs and meeting demand in growing regional markets like Uzbekistan.

    Executive Summary
    SWOT Analysis
    Kazakhstan Pharmaceuticals And Healthcare SWOT
    Kazakhstan Political SWOT
    Kazakhstan Economic SWOT
    Kazakhstan - Business Environment Rating

    Table: Central And Eastern Europe (CEE) Pharmaceutical And Healthcare Business Environment Ratings, Q310
    Limits of Potential Returns
    Risks to Realisation of Returns
    Kazakhstan - Market Summary
    Regulatory Regime
    Intellectual Property Environment
    Counterfeit Drugs
    Pricing and Reimbursement Regime

    Table: Price Components And Add-Ons For Imported And Locally Produced Generic Medicines (KZT)
    Recent Pricing and Reimbursement Developments
    Industry Developments
    Healthcare Sector

    Table: Top 10 Manufacturers By Value Of Hospital Purchases

    Table: Top 10 INNs By Value Of Hospital Purchases
    Healthcare Sector Financing

    Table: Top 10 ATC Groups By Value Of Hospital Purchases

    Table: Top 10 ATC Groups By Retail Pharmacy Sales
    Domestic Pharmaceutical Industry
    Recent Domestic Industry Developments
    Wholesale and Retail
    Recent Wholesale and Retail Developments
    Foreign Pharmaceutical Industry
    Recent Foreign Industry Developments
    Clinical Trials
    Medical Devices

    Table: Medical Devices Market In Kazakhstan, 2006-2008 (US$mn)
    Industry Forecast Scenario
    Overall Market Forecast
    Key Growth Factors - Industry
    Key Growth Factors - Macroeconomic

    Table: Kazakhstan - Economic Activity
    Prescription Market Forecast
    OTC Market Forecast
    Patented Market Forecast
    Generics Market Forecast
    Export/Import Market Forecasts
    Other Healthcare Data Forecasts
    Key Risks to BMI's Forecast Scenario
    Competitive Landscape

    Table: Top 10 Manufacturers By Retail Pharmacy Sales

    Table: Top 10 Trade Names By Value Of Retail Pharmacy Sales
    Company Monitor
    Indigenous Companies
    Romat FK
    Foreign Companies
    Novartis (Lek & Sandoz)
    GlaxoSmithKline (GSK)
    Merck & Co
    Country Snapshot: Kazakhstan Demographic Data
    Section 1: Population

    Table: Demographic Indicators, 2005-2030

    Table: Rural/Urban Breakdown, 2005-2030
    Section 2: Education and Healthcare

    Table: Education, 2002-2005

    Table: Vital Statistics, 2005-2030
    Section 3: Labour Market and Spending Power

    Table: Employment Indicators, 1999-2004

    Table: Consumer Expenditure, 2000-2012 (US$)

    Table: Average Annual Wages, 2000-2012
    BMI Methodology
    How We Generate Our Pharmaceutical Industry Forecasts
    Pharmaceutical Business Environment Ratings Methodology
    Ratings Overview

    Table: Pharmaceutical Business Environment Indicators

    Table: Weighting Of Components
    Forecast Tables

    Browse complete Report on: http://www.reportsandreports.com/market-reports/kazakhstan-pharmaceuticals-and-healthcare-report-q3-2010/

    Browse all Pharmaceuticals Market Research Reports on:

    Browse all Business Monitor International Market Research Reports on:

    Browse all Latest Report on:

    Related Reports:

    Bangladesh Pharmaceuticals and Healthcare Report Q3 2010

    Chile Pharmaceuticals and Healthcare Report Q3 2010

    Morocco Pharmaceuticals and Healthcare Report Q3 2010

    About Us:
    Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004
    Website: http://www.reportsandreports.com/
    Blog: http://reportsnreports.wordpress.com/
    Blog: http://reportsandreports.blogspot.com/

  • FB Icon Twitter Icon In-Icon
Contact Information